IL-6 mediated renal tubular cell senescence via GATA2/ SERPINE1 pathway

Author:

lin xiaoxi1,Sun Keke1,Liu Qihui1,Zhao Yibo1,Zhang Yan1,Shou Songtao1,Chai Yanfen1,Jin Heng1

Affiliation:

1. Tianjin Medical University General Hospital

Abstract

Abstract Background Acute kidney injury due to crush syndrome is a major life-threatening complication characterized by high morbidity and mortality. The role of senescence in the progression of acute kidney injury is receiving increasing attention. Our previous study has shown that remote ischemic postconditioning can attenuate kidney cell senescence and serum IL-6 from ischemia-reperfusion injury after crush injury. This raises the question of what role IL-6 plays in the progression of CS-AKI. The aim of this study was to investigate the role of IL-6 in CS-AKI. Methods Hk-2 cells were treated with 150uM ferrous myoglobin to mimic CS-AKI at the cellular level. Cells were harvested after 24 hours or treated with 100ug/ml tocilizumab for another 24 hours. RNA sequencing was performed on myoglobin and tocilizumab treated cells. The cell cycle and the percentage of senescent cells were detected by flow cytometry. The expression levels of SERPINE1, GATA2, p53, p21 were detected by real-time PCR and Western blot. The binding effect of SERPINE1 and GATA2 was verified by dual luciferase gene reporter assay. Results RNA sequencing revealed genes down-regulated by tocilizumab in HK-2 cells, including GATA2 and SERPINE1. qPCR and Western blotting confirmed that GATA2, SERPINE1, p53 and p21 expression decreased after tocilizumab treatment. The dual luciferase gene reporter verified that GATA2 acts on the promoter of SERPINE1 (PAI-1) to initiate SERPINE1 transcription. Conclusions In a word, IL-6 activates the p53/ P21 pathway through GATA2/SERPINE1, which triggers senescence in CS-AKI and then promotes the progression of AKI (Fig. 1 graphical abstract).

Publisher

Research Square Platform LLC

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3